Prasugrel/aspirin - Torrent Pharmaceuticals

Drug Profile

Prasugrel/aspirin - Torrent Pharmaceuticals

Alternative Names: Aspirin/Prasugrel; Prax A 75

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator Torrent Pharmaceuticals
  • Class Cyclopropanes; Fluorobenzenes; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules; Thienopyridines
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute coronary syndromes

Most Recent Events

  • 12 Sep 2016 Torrent Pharmaceuticals plans a phase IV trial for Acute coronary syndrome in India (CTRI/2016/08/007228)
  • 31 Aug 2016 Launched for Acute coronary syndromes in India before August 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top